Transcript
Hi, I'm Dr Yasir Elamin, Assistant Professor of Thoracic Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas.
The second abstract that I would like to highlight is abstract 9518, which is the updated overall survival and safety data from the randomized phase 3 ALEX study of alectinib versus crizotinib in untreated ALK-positive lung cancer.
I'll remind you that the investigator-assessed PFS, which is the primary end point, was reported last year and showed a PFS of 35 months with alectinib versus 11 months with crizotinib. In this abstract, office presented updated OS data with a median duration of follow-up of around 48 months with alectinib.
The median OS [with alectinib] is not reached; however, the median OS with crizotinib is 57 months.
The remarkable finding of this study is the 5-year survival rate of 62.5% with alectinib. This is probably the best 5-year survival outcomes from any trial to date for patients with metastatic lung cancer.
In fact, these outcomes are comparable to surgically-resected stage II disease.
I think this is an important milestone, and it shows that if we find the right target and the right drug, we achieve these amazing outcomes.
